Glecaprevir

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 291 publications

A Database-Derived Global Overview of HCV Resistance-Associated Substitutions: Characterizing Genotypic, Regional, and Temporal Heterogeneity.

A Database-Derived Global Overview of HCV Resistance-Associated Substitutions: Characterizing Genotypic, Regional, and Temporal Heterogeneity.

Journal: International journal of molecular sciences

Published: April 28, 2026

Phospholipid-driven conformational switching of HCV NS5A links protein folding to replication membrane remodeling.

Phospholipid-driven conformational switching of HCV NS5A links protein folding to replication membrane remodeling.

Journal: Science advances

Published: April 03, 2026

Antiviral treatment for chronic viral hepatitis B and C in children in Ostrava

Antiviral treatment for chronic viral hepatitis B and C in children in Ostrava

Journal: Klinicka mikrobiologie a infekcni lekarstvi

Published: February 24, 2026

Glecaprevir/Pibrentasvir for Post Traumatic Stress Disorder.

Glecaprevir/Pibrentasvir for Post Traumatic Stress Disorder.

Journal: Psychopharmacology bulletin

Published: January 14, 2026

Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection.

Population Pharmacokinetic Analysis of Glecaprevir and Pibrentasvir in Pediatric Patients ≥ 3 to < 18 Years of Age with Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection.

Journal: Clinical pharmacokinetics

Published: December 03, 2025

Recently acquired hepatitis C virus infection in people with HIV - what have we learned?

Recently acquired hepatitis C virus infection in people with HIV - what have we learned?

Journal: Current opinion in HIV and AIDS

Published: November 28, 2025

Repurposing antiviral drugs targeting RNA viruses: A focus on the fusion protein of human metapneumovirus.

Repurposing antiviral drugs targeting RNA viruses: A focus on the fusion protein of human metapneumovirus.

Journal: Northern clinics of Istanbul

Published: November 27, 2025

Successful Retreatment of Chronic Hepatitis C Virus Genotype 1A Infection With Glecaprevir/Pibrentasvir in a Pediatric Patient With Developmental Disorder.

Successful Retreatment of Chronic Hepatitis C Virus Genotype 1A Infection With Glecaprevir/Pibrentasvir in a Pediatric Patient With Developmental Disorder.

Journal: In vivo (Athens, Greece)

Published: November 21, 2025

LIPA-driven reprogramming of tumor-associated macrophages shapes an immunosuppressive microenvironment in osteosarcoma.

LIPA-driven reprogramming of tumor-associated macrophages shapes an immunosuppressive microenvironment in osteosarcoma.

Journal: International immunopharmacology

Published: November 11, 2025

Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated Analysis.

Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated Analysis.

Journal: Infectious diseases and therapy

Published: November 06, 2025

Nummular Eczema as the Initial Extrahepatic Manifestation of Hepatitis C Virus Infection: A Case Report.

Nummular Eczema as the Initial Extrahepatic Manifestation of Hepatitis C Virus Infection: A Case Report.

Journal: Cureus

Published: August 04, 2025

Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C.

Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C.

Journal: International journal of hepatology

Published: July 17, 2025

Showing 1-12 of 291

Last Updated: 06/30/2026